Abstract

Background: Current American Heart Association guidelines recommend carotid revascularization for asymptomatic patients based on co-morbid conditions and life expectancy. Objective: To determine the rates and predictors of five year survival in elderly patients with asymptomatic carotid artery stenosis who underwent either surgical or endovascular treatment. Methods: The study cohort included a representative sample of fee-for-service Medicare beneficiaries aged ≥65 years who underwent endovascular or surgical treatment for asymptomatic carotid artery stenosis with post-procedure follow-up of 3.4 (±1.7) years. The rates of 5 year survival were determined using Kaplan Meir survival methods. Cox proportional hazards analysis was used to assess the relative risk (RR) of all-cause mortality for patients in presence of selected co-morbidities including ischemic heart disease, chronic renal failure, and atrial fibrillation after adjusting for potential confounders such as age, gender, race/ethnicity and procedure type. Results: A total of 22177 patients with asymptomatic carotid artery stenosis were treated with either endovascular (n=2144) or surgical treatment (n=20033). The overall estimated 5 year survival rate was 95.3% (95% CI 95.0-95.6 %); and 95.5% and 93.8% in patients treated with surgical and endovascular treatments, respectively. After adjusting for potential confounders, relative risks of all-cause five year mortality was significantly higher among patients with atrial fibrillation (relative risk [RR] 1.9, 95% confidence interval [CI] 1.6-2.2) and those with chronic renal failure (RR 2.1, 95% CI1.7-2.6). Concurrent ischemic heart disease did not affect the all-cause mortality (RR 1.1, 95% CI0.9-1.3). Conclusion: Risks and benefits must be carefully weighed prior to carotid revascularization in elderly patients with asymptomatic carotid artery stenosis who have concurrent atrial fibrillation or chronic renal failure.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call